Show Notes
How do you commercialize regenerative medicine, and why is it so challenging? What does it take to build a successful biotech startup? And are revolutionary regenerative medicine solutions closer than we think?
In this episode, our guest is Marianne van der Steen, Professor of Entrepreneurship in Healthcare and Chief Business Development Officer at the MERLN Institute for Technology-Inspired Regenerative Medicine in the Netherlands.
Prof. van der Steen is a founding director of REGMED XB, a translational institute with an investment of 250 million euros, which translates groundbreaking regenerative medicine technologies into commercial products and companies.
Her expertise spans across not only research in biomedical entrepreneurship, but also translation of regenerative medicine into market-ready solutions, co-founding of game-changing ventures, and bridging the gap between scientists, businesspeople, and policymakers. With over 15 years of experience in scaling regenerative medicine startups, mentoring entrepreneurs, and making transatlantic collaboration possible, she is the one shaping the future of regenerative medicine.
If you want to learn more about the companies and institutes mentioned in the episode, please follow the links below:
MERLN Institute for Technology-Inspired Regenerative Medicine –https://merlninstitute.com RegMed XB –https://regmedxb.com California Institure for Regenerative Medicine (CIRM) –https://www.cirm.ca.gov MIRA University of Twente –https://www.utwente.nl/en/news/2010/3/116725/mira-ambitious-plan-for-the-future Hummingbird Biomedical –https://www.hummingbirdbiomedical.com ReGen Biomedical – https://www.regenbiomedical.com Vertex Pharmaceuticals –https://www.vrtx.com/home/ Mayo Clinic –https://www.mayoclinic.org Nextkidney –https://nextkidney.com
Timestamps: 00:00 Introduction to Biomed unleashed 00:39 Guest Introduction 01:32 Welcome 01:45 What has inspired you to focus on valorization of scientific knowledge? 03:35 Why valorization of specifically regenerative medicine projects? 05:14 Why is it challenging to commercialize regenerative medicine compared to other fields? 07:23 What is the idea behind the RegMed XB company that you co-founded? 09:34 What are the Moonshots in RegMed XB company, and why these specific Moonshots were chosen? 12:00 How do you foster international and public-private collaborations within regenerative medicine field? 14:29 What stage of product development are you typically involved in? 17:05 Do you teach scientists entrepreneurial skills? 20:08 What advice would you give to scientists who aspire to bring their knowledge to commercial applications? 22:34 How do you tackle failures, and what is a failure? 27:30 Why and how transatlantic collaboration between US and the Netherlands is important in the regenerative medicine field? 32:08 Looking into the future, how close are we to treating patients with engineered/artificial/lab-grown human tissues? 36:47 Future of in-silico trials 38:34 How can we measure success? 41:06 What is the most successful project you helped to upscale? 43:14 Last question! 45:15 Final thoughts 46:09 Meet Biomed Unleashed Team 46:37 Biomed Unleashed Outro
More from Biomed Unleashed
What does it take to guide scientific research and higher education at one of the world's best young universities?
What does it take to build one of Europe’s leading research institutes in Regenerative Medicine? In this inspiring conversation, we speak with Professor Clemens van Blitterswijk, a pioneer in tissue engineering and founder of the MERLN Institute for Technology-Inspired Regenerative Medicine in Maastricht, the Netherlands. The conversation touches on many turning points: building companies during crises, navigating the choice between academia and business, and leading a remarkable transfer of sixteen colleagues to establish a new research institute. Clemens reflects on the right time to commercialize discoveries and how coincidental findings can lead to breakthroughs in top journals. He shares insights on helping startups through RegMed XB and the delicate art of knowing when to push forward and when to stop. We also discussed why art and science are more closely related than we think. From biomaterials that grow bone to Clemens’ vision for high-throughput technologies, this interview reveals a scientist-entrepreneur who has not only advanced regenerative medicine but also built bridges between universities, startups, and patients – pushing regenerative medicine field forward.
What does it take to lead the future of regenerative medicine? Professor Martijn van Griensven shared the experiences that have shaped his journey from his early days as Germany’s youngest professor to his current work as a leading mind in biomedical research and head of the cBITE department at the MERLN Institute. We explored how bones heal, and why sometimes they don’t, and what role the immune system plays when regeneration breaks down. We dove into the molecular world of RNA therapies and their potential to modulate immune responses and help tissues rebuild themselves. We talked about the practical challenges of bringing these therapies into the clinic, the role of AI in tailoring treatments to each patient, and what the future might hold. For Professor van Griensven, it’s not just about molecules and machines, it’s about curiosity, perseverance, and asking the right questions.
How do you get hold of the viruses and, with their help, cure some of the deadliest diseases known to humanity?
What is personalised medicine and how it revolutionizes our understanding of classic medical approaches?